Amneal Pharmaceuticals Inc (AMRX)
NASDAQ:AMRX
Top Page
Amneal Pharmaceuticals
(NASDAQ:AMRX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$12.00
▼(-5.59% Downside)
Action:ReiteratedDate:02/28/26
The score is held back mainly by weak valuation (very high P/E) and a still-mixed financial profile marked by historically stressed balance-sheet periods and volatile profitability, despite improving cash generation. Earnings-call guidance is constructive with expected margin/earnings growth and continued deleveraging, but technical signals show cautious near-term momentum.
Positive Factors
Cash generation strength
Consistent positive operating and free cash flow provides durable internal funding for capex, launch cadence and debt reduction. Strong cash conversion since 2023 increases financial flexibility to fund complex generics, biosimilars and GLP‑1 manufacturing without relying solely on external capital.
Negative Factors
Execution & timing risk
The business transformation relies on many interdependent milestones across R&D, regulatory approvals and manufacturing scale‑up. Delays or commercialization setbacks would push out revenue and margin benefits, making near‑term forecasts sensitive to execution and undermining the durability of projected improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation strength
Consistent positive operating and free cash flow provides durable internal funding for capex, launch cadence and debt reduction. Strong cash conversion since 2023 increases financial flexibility to fund complex generics, biosimilars and GLP‑1 manufacturing without relying solely on external capital.
Read all positive factors
Amneal Pharmaceuticals (AMRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.00B
Dividend YieldN/A
Average Volume (3M)2.08M
Price to Earnings (P/E)54.8
Beta (1Y)0.89
Revenue Growth9.50%
EPS GrowthN/A
CountryUS
Employees8,300
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.21
Shares Outstanding314,629,100
10 Day Avg. Volume1,456,997
30 Day Avg. Volume2,080,198
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)-55.77
Price to Sales (P/S)1.31
P/FCF Ratio14.63
Enterprise Value/Market Cap1.61
Enterprise Value/Revenue2.13
Enterprise Value/Gross Profit5.77
Enterprise Value/Ebitda10.64
Forecast
1Y Price Target
$16.75Price Target Upside31.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.99
Revenue Forecast (FY)$3.12B
Amneal Pharmaceuticals Business Overview & Revenue Model
Company Description
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through thr...
How the Company Makes Money
Amneal makes money primarily by selling pharmaceutical products to wholesalers, pharmacies, hospitals, distributors, and other healthcare-channel customers. Its core revenue stream is the sale of generic prescription drugs: it develops or in-licen...
Amneal Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 27, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 01, 2026
Earnings Call Sentiment Positive
The call communicated solid financial progress (8% revenue growth, double‑digit EBITDA expansion, meaningful EPS improvement), meaningful pipeline and commercial traction (complex generics, biosimilars, specialty launches like Krexone and an auto‑injector), and clear balance sheet improvement. Management also flagged near‑term headwinds and timing risks—AvKARE revenue reset, flat Affordable Medicines in Q4, generic erosion in specialty, and supply‑chain/timing for certain launches—which cap near‑term upside. On balance the company appears to be transitioning to higher‑value, higher‑margin products with deliberate investments (biosimilars, GLP‑1 manufacturing) and improved financial flexibility, while acknowledging execution and timing risks that may temper 2026 results.Positive Updates
Consolidated Revenue and Profitability Growth (2025)
Full-year 2025 revenue of $3.0B, up 8% year-over-year; full-year adjusted EBITDA of $688M, up 10%; full-year adjusted EPS $0.83, up 43%.
Negative Updates
Affordable Medicines Near-Term Volatility
Affordable Medicines segment was essentially flat in Q4 at $437M and only grew 4% for full year 2025; management highlighted timing of launches as a cause and expects acceleration in 2026–2027 but near-term growth remains dependent on successful rollouts.
Read all updates
Q4-2025 Updates
Positive
Negative
Consolidated Revenue and Profitability Growth (2025)
Full-year 2025 revenue of $3.0B, up 8% year-over-year; full-year adjusted EBITDA of $688M, up 10%; full-year adjusted EPS $0.83, up 43%.
Read all positive updates
Company Guidance
Management guided 2026 revenue of $3.05–3.15 billion (up 1–4%), with Affordable Medicines growing 7–8%, Specialty roughly flat, and AvKARE expected at $625–700 million (vs. $745M in 2025); they forecast adjusted gross margin >44% (~+100 bps), adjusted EBITDA of $720–760 million (up 5–10%), and adjusted EPS of $0.93–1.03 (up 12–20%). They expect operating cash flow of $325–375 million (vs. ~$340M in 2025), CapEx of ~$110 million (~3% of revenue), a gradual quarterly build as launches ramp, and continued balance‑sheet improvement (net leverage 3.5x at year‑end 2025 and a weighted‑average cost of debt around 6.8% in 2026 with expected lower interest expense).Amneal Pharmaceuticals Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
41
Neutral
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.02B | 2.79B | 2.39B | 2.21B | 2.09B |
| Gross Profit | 1.14B | 1.02B | 863.87M | 791.46M | 768.97M |
| EBITDA | 603.87M | 439.77M | 500.78M | 440.21M | 401.10M |
| Net Income | 72.06M | -116.89M | -83.99M | -129.99M | 10.62M |
Balance Sheet | |||||
| Total Assets | 3.68B | 3.50B | 3.47B | 3.80B | 3.94B |
| Cash, Cash Equivalents and Short-Term Investments | 310.87M | 112.42M | 93.74M | 27.80M | 247.79M |
| Total Debt | 2.74B | 2.59B | 2.75B | 2.85B | 2.88B |
| Total Liabilities | 3.67B | 3.55B | 3.41B | 3.59B | 3.57B |
| Stockholders Equity | -70.79M | -109.27M | 19.78M | 298.42M | 360.34M |
Cash Flow | |||||
| Free Cash Flow | 269.93M | 220.11M | 276.39M | -25.50M | 194.09M |
| Operating Cash Flow | 339.99M | 295.10M | 345.58M | 65.10M | 241.82M |
| Investing Cash Flow | -112.26M | -63.00M | -69.19M | -174.31M | -194.18M |
| Financing Cash Flow | -31.53M | -211.79M | -212.57M | -106.62M | -138.12M |
Amneal Pharmaceuticals Technical Analysis
Positive
12.71
Price Trends
13.41
Negative
12.98
Negative
11.18
Positive
Market Momentum
-0.23
Negative
51.20
Neutral
70.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRX, the sentiment is Positive. The current price of 12.71 is above the 20-day moving average (MA) of 12.23, below the 50-day MA of 13.41, and above the 200-day MA of 11.18, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 51.20 is Neutral, neither overbought nor oversold. The STOCH value of 70.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMRX.
Amneal Pharmaceuticals Risk Analysis
Amneal Pharmaceuticals disclosed 57 risk factors in its most recent earnings report. Amneal Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amneal Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.77B | 14.40 | 15.55% | ― | 48.87% | ― | |
61 Neutral | $925.55M | 12.76 | 12.76% | ― | -0.03% | -27.66% | |
55 Neutral | $2.97B | -72.78 | -3.67% | ― | 4.54% | -130.59% | |
54 Neutral | $4.00B | 54.80 | -67.91% | ― | 9.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.49B | -1.35 | -35.16% | 8.48% | -2.55% | 66.00% | |
46 Neutral | $1.12B | -3.30 | -11.92% | ― | 55.38% | ― |
* Healthcare Sector Average
AMRX
Amneal Pharmaceuticals
12.71
5.28
71.06%
PRGO
Perrigo Company
10.83
-13.36
-55.23%
SUPN
Supernus Pharmaceuticals
51.61
19.85
62.50%
ANIP
ANI Pharmaceuticals
79.01
13.00
19.69%
AMPH
Amphastar Pharmaceuticals
20.40
-4.83
-19.14%
ALVO
Alvotech
3.58
-5.16
-59.04%
Amneal Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial Disclosures
Amneal Posts Strong Q4 Results and Raises 2026 Outlook
Positive
Feb 27, 2026
On February 27, 2026, Amneal reported that fourth-quarter 2025 net revenue rose 11% year over year to $814 million, with GAAP net income swinging to a $35 million profit from a $31 million loss and adjusted EBITDA climbing 13% to $175 million. Spe...
Business Operations and StrategyPrivate Placements and Financing
Amneal Pharmaceuticals Refinances Term Loans, Lowers Interest Costs
Positive
Feb 3, 2026
On February 2, 2026, Amneal Pharmaceuticals’ subsidiary, Amneal Pharmaceuticals LLC, and certain of its subsidiaries entered into a second amendment to their November 14, 2023 term loan credit agreement, refinancing and partially converting ...
Business Operations and StrategyLegal Proceedings
Amneal Finalizes Nationwide Opioid Settlement Implementation Plan
Negative
Jan 28, 2026
On January 23, 2026, Amneal Pharmaceuticals said it would implement a nationwide opioids settlement after securing sufficient participation from all eligible state and territorial attorneys general and all subdivisions that had sued the company, w...
Financial DisclosuresRegulatory Filings and Compliance
Amneal Pharmaceuticals Files Routine Regulation FD Disclosure Report
Neutral
Jan 13, 2026
On January 13, 2026, Amneal Pharmaceuticals, Inc. filed a report under the Securities Exchange Act of 1934, formally executed on behalf of the company by Executive Vice President and Chief Financial Officer Anastasios Konidaris, who also serves as...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.